AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01217411 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT03260842 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Bio-Specimen Collection
Description: Collection of bio-specimens and observation over time.
Study NCT04315038 — intervention group
Intervention type: PROCEDURE
Intervention: spinal anesthesia
Description: Plan to enroll 200 health volunteers and 40 neurodegenerative diseases patients with received spinal anesthesia. Blood will be collected at time point of pre-anesthesia 10 minutes and CSF samples will be collected at time point during spinal anesthesia induction. Blood will be collected, drawn into EDTA-coated tube.
Study NCT00620165 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levetiracetam
Description: Subjects will receive levetiracetam titrated up over 6 weeks to a maximum dose of 3000 milligrams (mg) per day, and then continue at 1500 mg twice daily for an additional 6 weeks.
Study NCT01217411 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole-Brain Radiotherapy
Description: Undergo WBRT
Study NCT00620165 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Subjects will receive identical placebo titrated up over 6 weeks to a maximum daily dose, and then continue twice daily for an additional 6 weeks.
Study NCT03944876 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A
Description: Botulinum toxin 25 Allergan units in 0.5 ml Sodium Chloride (NaCl) 0.9 % Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Study NCT03944876 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0.5 ml Sodium Chloride (NaCl) 0.9% Braun. One injection in the headache side of the face, targeted at the sphenopalatine ganglion (SPG)
Study NCT02630277 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Aflibercept Injection 2.0 mg
Study NCT01780389 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Open-label flexibly dosed milnacipran
Study NCT00830427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-00610355
Description: 100 mcg, QD, dry powder inhaler
Study NCT00830427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF - 00610355
Description: 600 mcg, QD, dry powder inhaler
Study NCT02677051 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sulforaphane
Description: Sulforaphane (1-isothiocyanato-4R- (methylsulfinyl)butane) is an isothiocyanate derived from the action of the plant enzyme myrosinase on glucosinolates including glucoraphanin and comes from consumption of many cruciferous vegetables.
Study NCT02677051 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02302833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cabozantinib S-malate
Description: Given PO
Study NCT02302833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02302833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT00830427 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: QD, dry powder inhaler
Study NCT00830427 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF - 00610355
Description: 300 mcg, QD, dry powder inhaler
Study NCT04087655 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Eight weeks of interval exercise training
Study NCT04114084 — intervention group
Intervention type: PROCEDURE
Intervention: Bone Marrow Aspirate and Biopsy
Description: The aspirate sample obtained for research at the time a standard-of-care biopsy is taking place will be approximately 40cc. Bone marrow aspiration removes bone marrow fluid and cells through a needle placed into the bone. Usually this sample is taken from the back of the pelvic bone, but it may also be taken from the sternum or the front of the pelvic bone. A bone marrow biopsy removes bone with the marrow inside and is done prior to the aspirate. Each biopsy and aspirate procedure takes approximately 15 minutes total. Bone marrow aspirate may be collected in a separate tube for research or collected from the standard-of-care specimen with left-over aspirate not otherwise needed for clinical purposes, or from previous procedures.
Study NCT03008005 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dronabinol Cap 10 milligrams (MG)
Description: Dronabinol (10mg) is administered only once (approximately 120 min prior to MR scanning in Visit 3) by the oral route and is placed in an opaque capsule with dextrose filler.
Study NCT02597257 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine HCl
Description: lidocaine continuous infusion
Study NCT00921505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablet ibuprofen 400 mg oral single dose (1 tablet)
Study NCT02597257 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Normal saline continuous infusion
Study NCT01354470 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Modafinil
Description: 600 mg Modafinil capsule
Study NCT04997551 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Colchcine
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day
Study NCT04997551 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Colchcine
Description: In patients not taking lopinavir / ritonavir or any other CYP3A4 or P-glycoprotein inhibitor drugs:~* Day 1: 1 single dose of 1 mg orally, in a single dose.~* Days 2 to 6: 0.5 mg every 12 hours v.o.~* Days 7 to 14: 0.5 mg / 24 hours v.o. In patients taking drugs that inhibit the CYP3A4 system or the P-glycoprotein, these drugs will be attempted to be discontinued. The dose in these cases will be: o 0.5 mg every 72 hours v.o. while taking the drug that interacts.~or 0.5 mg every 24 hours v.o. when, after suspending the interacting drug, at least 5 half-lives of the suspended drug have elapsed, from the last intake of said drug (in the case of lopinavir / ritonavir this would be a total of 24-30 hours) until the 14th day.~In patients older than 80 years or patients with CKD-EPI estimated glomerular renal failure filtration rate between 30 and 50 ml / min / 1.73 m2), the colchicine / placebo dose will be:~o Days 1 to 14: 0.5 mg / day
Study NCT02958176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: HRV Biofeedback
Description: At-home heart rate variability biofeedback using Elite HRV app and Polar H7 chest strap
Study NCT02958176 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autogenic Training
Description: Autogenic training recording provided on a CD
Study NCT00688844 — intervention group
Intervention type: DRUG
Intervention: KuvanTM Therapy
Description: BH4 treatment was prescribed by each participant's medical provider, not an intervention that was assigned as part of the current study.
Study NCT01196598 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercises
Description: Three individual initial sessions for learn about pelvic floor muscle localization and function; receive lifestyle advice and practice the exercises correctly.~The control group receive only lifestyle advice.~Followed by three months of home training with appointments each two weeks with physiotherapist.
Study NCT03008616 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: AMAG-423 (digoxin immune fab)
Description: AMAG-423 (digoxin immune fab) 3.2 mg/kg, 30 minute IV infusion, every 6 hours x 4 days
Study NCT03008616 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline, 30 minute IV infusion, every 6 hours x 4 days
Study NCT01721551 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Training will include a 45-60 min aerobic training on a rehabilitation cycle ergometer (Monark Rehab Trainer 881E) in the supine position during dialysis session. The intensity will progress from 30-40% of the maximum exercise power to 60-70%.
Study NCT01721551 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Treatment
Description: The CON group received no intervention but the usual treatment
Study NCT03039816 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Nasaleze
Description: Nasaleze cellulose powder
Study NCT03039816 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Lactose powder in the same plastic container as Nasaleze and with the same taste
Study NCT03431636 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immersion
Description: cold water immersion
Study NCT03431636 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ice pack
Description: ice packs through the body
Study NCT03431636 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: rest
Description: seated rest
Study NCT00259194 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Moving
Description: The patients are allowed to lift their head, arms and legs during the 2 hours.
Study NCT00259194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Moving
Description: The patients are told not to move, to keep their legs and upper arms down and not to lift the head from the pillow in these 2 hours.
Study NCT00913276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Propofol
Study NCT00913276 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sevoflurane
Study NCT02667769 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Fasting day
Description: A day of fasting started at 18.00 clock with a blood glucose test and is only started when on the same day no significant hypoglycemia (blood glucose \<55 mg / dl) occurred, and when at 18.00 clock the blood sugar in the defined target range (70-180 mg / dl) is. Carried out during the fasting day standardized blood samples for measurement of plasma glucose with an appropriate laboratory method at 18.00, 20:00, 22:00, 12:00, 2:00, 4:00, 6:45, 9:00, 12:00, 14:00 and again at 18.00 clock. Because the determination of plasma glucose in the laboratory will take some time, is always for guidance and also measured with a fast measurement method, in order to treat at high levels of blood sugar with additional insulin correction, and to treat hypoglycaemia low blood sugar or to prevent hypoglycaemia.
Study NCT04156737 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony plus IOL Model ZHR00V
Description: IOL replaces the natural lens removed during cataract surgery
Study NCT04156737 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Trifocal Intraocular lens
Description: IOL replaces the natural lens removed during cataract surgery
Study NCT01886222 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Long-term mild hypothermia
Description: Hypothermia will be induced within 6 hours of injury and maintained at 34-35℃ for 5 days.Then the patients will be passively rewarmed to a temperature of 36 to 37˚C at a rate no greater than 0.5˚C/4 hours.
Study NCT01886222 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Normothermia
Description: Patients assigned to the normothermia group will be kept at 36-37℃.
Study NCT00283842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DVS SR
Study NCT02049671 — intervention group
Intervention type: DRUG
Intervention: Growth Hormone Therapy
Study NCT00283842 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01949532 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection.
Study NCT04392934 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: a conservative physiotherapy protocol
Description: 5 minutes of ultrasound (Business Line US 50, Medical Italia, Italy) at a frequency of 1 MHz and intensity of 1.5 watts/cm², 20 minutes of conventional TENS (BTL-5000, UK ) applied to the patients. Then Codman's exercises, shoulder wheel activity, isometric exercises, range of motion exercises, capsular stretching, scapular stabilization exercises, and muscle strengthening exercises were done by patients. After the treatment, cold pack was applied to the shoulder for 10 minutes. The modalities in the treatment program were applied for a total of 20 sessions 5 days per week.
Study NCT04250402 — intervention group
Intervention type: PROCEDURE
Intervention: Resection
Description: Radical resection.
Study NCT03142958 — intervention group
Intervention type: DEVICE
Intervention: Integra Cadence Total Ankle System
Description: Primary or revision on total ankle replacement
Study NCT01530516 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Brackets plus Forsus springs
Description: Full brackets and after completion of level and alignment insertion of Class II correctors (Forsus spring devices).
Study NCT01530516 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xbow plus full brackets
Description: Xbow appliance to be inserted first. After anteroposterior changes have been completed full brackets will be bonded and occlusion fine tuned
Study NCT03182556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Electromyography-Biofeedback (EMG-BFB) training
Description: The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
Study NCT03182556 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Electromyography-Biofeedback (EMG-BFB) training
Description: The Chattanooga Intelect Advanced model was used with the surface EMG for 2 independent channels. The patient can observe on the screen as columns of varying their height in the function of the degree of muscular tension. Each session was configured as follows. First, a 2 minute period for adaptation and then we continue with a 2 minute period to establish the baseline. After that, a 7 minute training trial session to reduce the muscle tension as well as a pause of about 2 minutes. Then, it continued with two more trials of 7 minutes interleaved with another 2 minute break. Thus, the whole training lasts 29 minutes approximately. The pauses between the individual trials were intended to recover the baseline level to carry out a new trial which will start from a higher level of EMG.
Study NCT03182556 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aquatic exercise
Description: Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
Study NCT03182556 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Aquatic exercise
Description: Aquatic Exercise program (Biodanza exercises) was carried out in a swimming-pool with a water temperature of approximately 29 ° C, preceded by a shower at a temperature of about 33-35 °C. Each session lasts an hour and they will held twice a week (Monday and Wednesday) during a period of time of three months (12 weeks).
Study NCT00921505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ibuprofen
Description: Tablets (2 x 600 mg) oral single dose (2 tablets)
Study NCT00921505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol (acetaminophen) 1000 mg
Description: Tablets (2 x 500 mg) oral single dose (2 tablets)
Study NCT00921505 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paracetamol + ibuprofen
Description: Tablets (ibuprofen 400 mg + paracetamol (acetaminophen) 2 x 500 mg) single oral dose (3 tablets)
Study NCT00428727 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Controlled nitric oxide releasing patch
Description: daily application of nitric oxide patch during 90 days
Study NCT02923778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo tumor biopsy
Study NCT02923778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo collection of blood
Study NCT02923778 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study NCT02923778 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT02923778 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Talimogene Laherparepvec
Description: Given IT or via intralesional injection
Study NCT02722096 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axillary block anesthesia with Ropivacaine and Lidocaine
Description: Axillary brachial plexus block anesthesia with injection of Ropivacaine and Lidocaine will be performed by anesthetist 30 to 45 minutes before surgery
Study NCT00428727 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo patch
Description: daily application during 90 days
Study NCT02369835 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dakin's solution
Description: Apply modified Dakin's solution (0.005 to 0.01%) topically
Study NCT02369835 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Applied topically
Study NCT01827540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cenicriviroc
Study NCT03747757 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy
Description: Undergo CBT
Study NCT01827540 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Study NCT02722096 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with Ropivacaine and Lidocaine
Description: Local subcutaneous infiltration of Ropivacaine and Lidocaine will be performed by anesthetist at the beginning of surgery
Study NCT03565965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Experimental training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves walking as of a first-person perspective, without any overt physical movement, in four different conditions: habitual speed, as fast as possible, overcoming obstacles and memorizing a name of a specific medication.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Study NCT03565965 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Control training
Description: Each block of MP consists of 5 mental walking attempts with 10 imagined steps. Participants, seated comfortably, eyes closed, will be asked to imagine themselves seated appreciating a beautiful landscape as of a first-person perspective, without any overt physical movement, in four different contexts: in a carriage, in a hot air balloon, in a boat and in a zepelin.~Each block of PP consists of 5 physical walking attempts, with 10 steps. Participants will be asked to walk in 4 different conditions: habitual speed,as fast as possible, overcoming obstacles and memorizing a name of a specific medication.
Study NCT04705038 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Education
Description: Brief educational session on surgical castration as an alternative to lifelong ADT for prostate cancer.
Study NCT03636711 — intervention group
Intervention type: OTHER
Intervention: antibiotic protocol, according to a syndromic approach
Description: Description of patients who benefited or not the antibiotic protocol, according to a syndromic approach and analysis of the causes of non-adherence to the protocols
Study NCT00300118 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: budesonide
Description: 9 mg
Study NCT03747757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT03747757 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02113813 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: naquotinib
Description: oral